Ekvivalence alternativních verzí Montrealského kognitivního testu


Autoři: O. Bezdíček 1,2;  H. Georgi 2;  E. Panenková 3;  S. M. Mcclintock 4,5;  T. Nikolai 1;  E. Růžička 1;  M. Kopeček 2,6
Působiště autorů: Department of Neurology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic 1;  National Institute of Mental Health, Klecany, Czech Republic 2;  Department of Psychology, Faculty of Arts, Charles University, Prague, Czech Republic 3;  Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA 4;  Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA 5;  Department of Psychiatry, Third Faculty of Medicine, Charles University, Prague, Czech Republic 6
Vyšlo v časopise: Cesk Slov Neurol N 2019; 115(3): 332-340
Kategorie: Původní práce
doi: 10.14735/amcsnn2019332

Souhrn

Cíl: Cílem studie je popis psychometrických vlastností standardní verze Montrealského kognitivního testu (MoCA-SV) a dvou alternativních forem (MoCA-AV). V české verzi je nedostatek informací o test-retestovém efektu a reliabilitě MoCA.

Metodika: Sedmdesát kognitivně zdravých osob (průměrný věk 50,33 ± 26,47) bylo vyšetřeno v jednom sezení pomocí MoCA-SV a MoCA-AV (7.2 a 7.3) ve znáhodněném pořadí.

Výsledky: Mezi MoCA-SV a MoCA-AV 7.3 neexistuje statisticky významný rozdíl v celkovém hrubém skóru, zatímco v MoCA-AV 7.2 je obtížnější verze testu ve srovnání s MoCA-SV a MoCA-AV 7.3. Hlubší analýza odhalila další rozdíly mezi subtesty verzí MoCA. Celkové skóry MoCA však ve všech verzích naznačují přijatelné hodnoty konvergentní a diskriminační validity.

Závěr: Naše data naznačují, že MoCA-SV i MoCA-AV 7.3 jsou ekvivalentní a užitečné pro opakovanou administraci a minimalizaci test-retestového efektu.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Klíčová slova:

Montrealský kognitivní test – reliabilita – ekvivalence – vnitřní konzistence – alternativní verze


Zdroje

1. Cullen B, O‘Neill B, Evans JJ et al. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry 2007; 78(8): 790–799. doi: 10.1136/ jnnp.2006.095414.

2. Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive impairment: a systematic review. Int J Geriatr Psychiatry 2009; 24(9): 902–915. doi: 10.1002/
 gps.2208.

3. Roalf DR, Moberg PJ, Xie SX et al. Comparative accuracies of two common screening instruments for classification of Alzheimer‘s disease, mild cognitive impairment, and healthy aging. Alzheimers Dement 2013; 9(5): 529–537. doi: 10.1016/ j.jalz.2012.10.001.

4. Bezdicek O, Cervenkova M, Moore TM et al. Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech version: validity in mild cognitive impairment Parkinson‘s disease and cross-cultural comparison. Assessment 2018: 1073191118778896. doi: 10.1177/ 1073191118778896.

5. Kopecek M, Stepankova H, Lukavsky J et al. Montreal cognitive assessment (MoCA): normative data for old and very old Czech adults. Appl Neuropsychol Adul 2017; 24(1): 23–29. doi: 10.1080/ 23279095.2015.1065261.

6. Anastasi A, Urbina S. Psychological testing. Upper Saddle River, NJ, USA: Prentice Hall/ Pearson Education 1997.

7. Goldberg TE, Harvey PD, Wesnes KA et al. Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer‘s disease randomized controlled trials. Alzheimers Dement 2015; 1(1): 103–111. doi: 10.1016/ j.dadm.2014.11.003.

8. Basso MR, Bornstein RA, Lang JM. Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 1999; 13(3): 283–292. doi: 10.1076/ clin.13.3.283.1743.

9. Cooley SA, Heaps JM, Bolzenius JD et al. Longitudinal change in performance on the Montreal Cognitive Assessment in older adults. Clin Neuropsychol 2015; 29(6): 824–835. doi: 10.1080/ 13854046.2015.1087596.

10. Beglinger LJ, Gaydos B, Tangphao-Daniels O et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 2005; 20(4): 517–529. doi: 10.1016/ j.acn.2004.12.003.

11. Calamia M, Markon K, Tranel D. The robust reliability of neuropsychological measures: meta-analyses of test-retest correlations. Clin Neuropsychol 2013; 27(7): 1077–1105. doi: 10.1080/ 13854046.2013.809795.

12. Helmstadter GC. Principles of psychological measurement: East Norwalk, CT, US: Appleton-Century-Crofts 1964.

13. Meyer JP. Reliability. Oxford: Oxford University Press 2010.

14. Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695–699. doi: 10.1111/ j.1532-5415.2005.53221.x.

15. MoCA Montreal – Cognitive Assessment. [online]. Available from URL: https: / / www.mocatest.org/ .

16. Dalrymple-Alford JC, MacAskill MR, Nakas CT et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75(19): 1717–1725. doi: 10.1212/ WNL.0b013e3181fc29c9.

17. Litvan I, Goldman JG, Troster AI et al. Dia­gnostic criteria for mild cognitive impairment in Parkinson‘s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27(3): 349–356. doi: 10.1002/ mds.24893.

18. Chertkow H, Nasreddine Z, Johns E et al. The Montreal cognitive assessment (MoCA): Validation of alternate forms and new recommendations for education corrections. Alzheimers Dement 2011; 7 (Suppl 4): S157.

19. Costa AS, Fimm B, Friesen P et al. Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. Dement Geriatr Cogn Disord 2012; 33(6): 379–384. doi: 10.1159/ 000340006.

20. Nasreddine ZS, Patel BB. Validation of Montreal Cognitive Assessment, MoCA, Alternate French Versions. Can J Neurol Sci 2016; 43(5): 665–671. doi: 10.1017/  cjn.2016.273.

21. Siciliano M, Chiorri C, Passaniti C et al. Comparison of alternate and original forms of the Montreal Cognitive Assessment (MoCA): an Italian normative study. Neurol Sci 2019; 40(4): 691–702. doi: 10.1007/ s10072-019-3700-7.

22. Wong A, Yiu S, Nasreddine Z et al. Validity and reliability of two alternate versions of the Montreal Cognitive Assessment (Hong Kong version) for screening of Mild Neurocognitive Disorder. Plos One 2018; 13(5): e0196344. doi: 10.1371/ journal.pone.0196344.

23. Gierus J, Mosiolek A, Koweszko T et al. [The Montreal Cognitive Assessment 7.2 – Polish adaptation and research on equivalency]. Psychiatr Pol 2015; 49(1): 171–179. doi: 10.12740/ PP/ 24748.

24. Lebedeva E, Huang M, Koski L. Comparison of alternate and original items on the Montreal Cognitive Assessment. Can Geriatr J 2016; 19(1): 15–18. doi: 10.5770/ cgj.19.
216.

25. Costa AS, Reich A, Fimm B et al. Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early Alzheimer‘s disease. Dement Geriatr Cogn Disord 2014; 37(1–2): 95–103. doi: 10.1159/ 000351864.

26. Bezdicek O, Balabanova P, Havrankova P et al.
A Comparison of the Czech version of the Montreal Cognitive Assessment test with the Mini Mental State Examination in identifying cognitive deficits in Parkinson‘s disease. Cesk Slov Neurol N 2010; 73/ 106(2):
150–156.

27. Fujiwara Y, Suzuki H, Yasunaga M et al. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 2010; 10(3): 225–232. doi: 10.1111/ j.1447-0594.2010.00585.x.

28. Lee JY, Dong Woo L, Cho SJ et al. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008; 21(2): 104–110. doi: 10.1177/ 0891988708316855.

29. Hu JB, Zhou WH, Hu SH et al. Cross-cultural difference and validation of the Chinese version of Montreal Cognitive Assessment in older adults residing in Eastern China: preliminary findings. Arch Gerontol Geriatr 2013; 56(1): 38–43. doi: 10.1016/ j.archger.2012.05.008.

30. Memoria CM, Yassuda MS, Nakano EY et al. Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. Int J Geriatr Psychiatry 2013; 28(1): 34–40. doi: 10.1002/ gps.3787.

31. Rahman TT, El Gaafary MM. Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatr Gerontol Int 2009; 9(1): 54–61. doi: 10.1111/ j.1447-0594.2008.00509.x.

32. Kopecek M, Bezdicek O, Sulc Z et al. Montreal Cognitive Assessment and Mini-Mental State Examination reliable change indices in healthy older adults. Int J Geriatr Psychiatry 2017; 32(8): 868–875. doi: 10.1002/ gps.4539.

33. Bernstein IH, Lacritz L, Barlow CE et al. Psychometric evaluation of the Montreal Cognitive Assessment (MoCA) in three diverse samples. Clin Neuropsychol 2011; 25(1): 119–126. doi: 10.1080/ 13854046.2010.533
196.

34. Bezdicek O, Majerova V, Novak M et al. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington‘s disease. Appl Neuropsychol Adult 2013; 20(1): 33–40. doi: 10.1080/ 09084282.2012.670158.

35. Freitas S, Simoes MR, Maroco J et al. Construct validity of the Montreal Cognitive Assessment (MoCA). J Int Neuropsychol Soc 2012; 18(2): 242–250. doi: 10.1017/ S1355617711001573.

36. Krishnan K, Rossetti H, Hynan LS et al. Changes in Montreal Cognitive Assessment Scores Over Time. Assessment 2017; 24(6): 772–777. doi: 10.1177/ 1073191116654
217.

37. Price CC, Cunningham H, Coronado N et al. Clock drawing in the Montreal Cognitive Assessment: recommendations for dementia assessment. Dement Geriatr Cogn Disord 2011; 31(3): 179–187. doi: 10.1159/ 000324639.

38. Bezdicek O, Stepankova H, Martinec Nova­kova L et al. Toward the processing speed theory of activities of daily living in healthy aging: normative data of the Functional Activities Questionnaire. Aging Clin Exp
Res 2016; 28(2): 239–247. doi: 10.1007/ s40520-015-0413-5.

39. Bezdicek O, Michalec J, Nikolai T et al. Validity of the Montreal Cognitive Assessment in the Detection of mild cognitive impairment in Parkinson‘s disease. Cesk Slov Neurol N 2014; 77/ 110(1): 47–53.

40. Nikolai T, Stepankova H, Michalec J et al. Tests of verbal fluency, Czech normative study in older patients. Cesk Slov Neurol N 2015; 78/ 111(3): 292–299. doi: 10.14735/ amcsnn2015292.

41. Kopeček M, Kuncová A. Practice effect in Verbal fluency test and Assessment of an alternative version – pilot study. Psychiatrie 2006; 10(4): 211–215.

42. Sacks TL, Clark CR, Pols RG et al. Comparability and stability of performance of six alternate forms of the dodrill-stroop colour-word test. Clin Neuropsychol 1991; 5(3): 220–225. doi: 10.1080/ 13854049108404093.

43. Fernandez AL, Marcopulos BA. A comparison of normative data for the Trail Making Test from several countries: equivalence of norms and considerations for interpretation. Scand J Psychol 2008; 49(3): 239–246. doi: 10.1111/ j.1467-9450.2008.00637.x.

44. Bezdicek O, Moták L, Schretlen DJ et al. Sociocultural and language differences on the Trail Making Test. Arch Assessment Psychol 2016; 6(1): 33–48.

45. van de Vijver F, Tanzer NK. Bias and equivalence in cross-cultural assessment: an overview. Europ Rev Appl Psychol 1997; 47(4): 263–280.

46. Nunnally JC, Bernstein, I. H. Psychometric theory. 3rd ed. New York: McGraw-Hill, Inc. 1994.

Štítky
Dětská neurologie Neurochirurgie Neurologie
Článek Editorial

Článek vyšel v časopise

Česká a slovenská neurologie a neurochirurgie

Číslo 3

2019 Číslo 3

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
nový kurz
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: Prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Familiární transthyretinová periferní polyneuropatie
Autoři: MUDr. Radim Mazanec, Ph.D.

Diabetes mellitus a kardiovaskulární riziko, možnosti jeho ovlivnění
Autoři:

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se